$CELC has generated 14 mentions over the past 12 months from two distinct FinTwit voices, with the first mention appearing on September 29, 2025. @jacobplieth dominates the discussion with 23 mentions, while @adamfeuerstein has contributed 3 mentions. The most recent activity occurred on June 3, 2026, with ongoing discussion centered on the biotech sector.

Conversation around $CELC has focused on clinical trial data and conference presentations. Recent exchanges have examined differences between Phase 1b median progression-free survival metrics and results from the Viktoria-1 trial, with @jacobplieth noting that mutant cohorts achieved 14.6 months or 19.7 months with intermittent dosing. Coverage also included discussion of late-breaker presentations scheduled for the ASCO meeting in early June 2026.